I-MAB SPONS.ADS/1 -0001 - Asset Resilience Ratio
I-MAB SPONS.ADS/1 -0001 (0VY) has an Asset Resilience Ratio of 0.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how I-MAB SPONS.ADS/1 -0001's Asset Resilience Ratio has changed over time. Check I-MAB SPONS.ADS/1 -0001 strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down I-MAB SPONS.ADS/1 -0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of I-MAB SPONS.ADS/1 -0001.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €210.00K | 0.08% |
| Total Liquid Assets | €210.00K | 0.08% |
Asset Resilience Insights
- Limited Liquidity: I-MAB SPONS.ADS/1 -0001 maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
I-MAB SPONS.ADS/1 -0001 Industry Peers by Asset Resilience Ratio
Compare I-MAB SPONS.ADS/1 -0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for I-MAB SPONS.ADS/1 -0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.08% | €210.00K ≈ $245.51K |
€260.52 Million ≈ $304.58 Million |
-49.35pp |
| 2024-12-31 | 49.43% | €105.14 Million ≈ $122.91 Million |
€212.68 Million ≈ $248.65 Million |
+43.95pp |
| 2023-12-31 | 5.48% | €20.22 Million ≈ $23.64 Million |
€368.92 Million ≈ $431.31 Million |
-0.30pp |
| 2022-12-31 | 5.78% | €34.12 Million ≈ $39.89 Million |
€590.45 Million ≈ $690.29 Million |
-7.67pp |
| 2021-12-31 | 13.45% | €118.16 Million ≈ $138.14 Million |
€878.74 Million ≈ $1.03 Billion |
-- |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more